Published in BMC Neurosci on December 10, 2008
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | NCT01056965
Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis (2012) 1.31
Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum Mol Genet (2010) 1.03
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast (2012) 1.00
The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis (2010) 0.86
Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. EPMA J (2010) 0.80
Strategies to defeat ketamine-induced neonatal brain injury. Neuroscience (2012) 0.78
Novel strategies for the prevention of dementia from Alzheimer's disease. Dialogues Clin Neurosci (2009) 0.78
Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease. Open J Neurosci (2013) 0.78
Microtubule stabilising peptides rescue tau phenotypes in-vivo. Sci Rep (2016) 0.75
Timing of therapies for Down syndrome: the sooner, the better. Front Behav Neurosci (2015) 0.75
RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. Transl Psychiatry (2016) 0.75
ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol Psychiatry (2017) 0.75
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci (2004) 2.64
Tubulin microheterogeneity increases with rat brain maturation. Nature (1978) 1.91
A femtomolar-acting neuroprotective peptide. J Clin Invest (1996) 1.85
Monoclonal antibodies that recognize discrete forms of tubulin. Proc Natl Acad Sci U S A (1982) 1.63
Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem (1999) 1.60
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.41
Multiple tubulin forms are expressed by a single neurone. Nature (1981) 1.40
Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res (2003) 1.38
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev (2005) 1.16
Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther (2000) 1.14
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol (2006) 1.14
A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem (2004) 1.12
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem (2007) 1.12
Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem (2006) 1.08
Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther (1998) 1.04
The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis (2004) 1.03
NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke (2002) 1.01
Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci U S A (1999) 0.98
Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther (2004) 0.97
Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther (2007) 0.96
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol (2004) 0.96
Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol (2006) 0.93
Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD. J Neurochem (2004) 0.92
NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res (2007) 0.91
A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann N Y Acad Sci (1999) 0.88
A novel peptide prevents death in enriched neuronal cultures. Regul Pept (2000) 0.87
The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides (2003) 0.86
Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci (1996) 0.86
NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther (2006) 0.85
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci (2006) 0.81
Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Brain Res Dev Brain Res (1997) 0.80
Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Curr Alzheimer Res (2006) 0.78
The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis (2004) 1.03
NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res (2007) 0.91
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci (2006) 0.81